These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 5344299

  • 1. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
    Birkmayer W.
    Wien Klin Wochenschr; 1969 Sep 26; 81(39):677-9. PubMed ID: 5344299
    [No Abstract] [Full Text] [Related]

  • 2. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W, Butz P, Wiesendanger M.
    Dtsch Z Nervenheilkd; 1970 Sep 26; 197(1):85-100. PubMed ID: 5522871
    [No Abstract] [Full Text] [Related]

  • 3. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
    Kaufmann W, Butz P, Wiesendanger M.
    Dtsch Z Nervenheilkd; 1969 Dec 29; 197(1):85-100. PubMed ID: 5364658
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J, Klaiber R, Perret E, Ziegler WH.
    Dtsch Med Wochenschr; 1969 Dec 26; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A.
    Brux Med; 1972 Oct 26; 52(10):673-80. PubMed ID: 4656191
    [No Abstract] [Full Text] [Related]

  • 6. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D.
    Schweiz Med Wochenschr; 1972 Jan 22; 102(3):88-94. PubMed ID: 4551909
    [No Abstract] [Full Text] [Related]

  • 7. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W, Linauer W, Mentasti M, Riederer P.
    Wien Med Wochenschr; 1974 Jun 01; 124(22):340-4. PubMed ID: 4275492
    [No Abstract] [Full Text] [Related]

  • 8. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E, Cerillo A, Tata MR, Decina A.
    Acta Neurol (Napoli); 1973 Jun 01; 28(2):208-12. PubMed ID: 4709076
    [No Abstract] [Full Text] [Related]

  • 9. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW, Muschard F.
    Med Welt; 1973 Apr 27; 24(17):705-7. PubMed ID: 4750934
    [No Abstract] [Full Text] [Related]

  • 10. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 27; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

  • 11. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B, Steinhäusl H.
    Wien Med Wochenschr; 1972 Jun 17; 122(25):369-71. PubMed ID: 4558132
    [No Abstract] [Full Text] [Related]

  • 12. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J, Kase JC, Mena I, Palacios E.
    Rev Med Chil; 1973 Jun 17; 101(6):452-5. PubMed ID: 4764560
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J, Hemli JA, Alfandary I, Yahel M, Siegfried J.
    Wien Med Wochenschr; 1971 Oct 16; 121(42):741-5. PubMed ID: 5115985
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 15. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H.
    Wien Med Wochenschr; 1973 Jun 30; 123(26):433-5. PubMed ID: 4578743
    [No Abstract] [Full Text] [Related]

  • 16. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J, Markus E.
    Dtsch Med Wochenschr; 1972 Aug 25; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W, Eisenlohr JJ.
    Nervenarzt; 1974 Jan 25; 45(2):22-9. PubMed ID: 4601993
    [No Abstract] [Full Text] [Related]

  • 19. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G, Eisenring JJ, Gauthier G, Tissot R, de Ajuriaguerra J.
    Int J Neurol; 1972 Jan 25; 9(1):23-32. PubMed ID: 5086635
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974 Jan 25; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.